Doxorubicin-Eluting Intra-Arterial Therapy for Pediatric Extra-Abdominal Desmoid Fibromatoses: A Promising Approach for a Perplexing Disease

Eldad Elnekave*, Eli Atar, Shirah Amar, Elchanan Bruckheimer, Michael Knizhnik, Isaac Yaniv, Tal Dujovny, Meora Feinmesser, Shifra Ash

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Systemic doxorubicin is effective for desmoid fibromatosis (DF), but its use is limited by dose-dependent cardiotoxicity. A protocol of selective intra-arterial doxorubicin drug-eluting embolization (DEE) was designed to maximize target tissue efficacy of doxorubicin, while minimizing systemic exposure. Four children with recurrent or refractory DF were treated between 2014 and 2017. Tumor volumes were reduced by 54%–97% over a follow-up interval of 6–32 months. A single patient experienced transient lower extremity paresthesia (Common Terminology Criteria for Adverse Events grade I). Further investigation is needed to better establish these promising results for doxorubicin DEE in DF treatment.

Original languageEnglish
Pages (from-to)1376-1382
Number of pages7
JournalJournal of Vascular and Interventional Radiology
Volume29
Issue number10
DOIs
StatePublished - Oct 2018

Fingerprint

Dive into the research topics of 'Doxorubicin-Eluting Intra-Arterial Therapy for Pediatric Extra-Abdominal Desmoid Fibromatoses: A Promising Approach for a Perplexing Disease'. Together they form a unique fingerprint.

Cite this